Enlarged Prostate: Transurethral Needle Ablation
Topic Overview
Transurethral needle ablation (TUNA) is used to treat an enlarged prostate gland (benign prostatic hyperplasia, or BPH) with a needle-shaped device that delivers heat to very precise areas of the prostate. The device is inserted up the urethra inside a tube (catheter) that protects other tissues from being burned. The heat destroys specific areas that are blocking the flow of urine out of the bladder. This relieves BPH symptoms. The procedure does not require an overnight stay in the hospital but does require a spinal anesthetic. And usually a sedative is given to make you drowsy.
One study notes that after 1 year, TUNA reduced the American Urological Association (AUA) symptom index by 13 points while transurethral resection of the prostate (TURP) reduced it by 15 points.1 But TUNA was associated with fewer complications than TURP.2
Needle ablation has minimal complications, the most common being an inability to urinate (urinary retention) in the first 24 hours after surgery and pain while urinating. Sexual ability is generally not affected.1
The main advantages of this treatment are:
- It can be done without an overnight stay in the hospital.
- It has a short recovery time, although the symptoms may take longer to improve.
- It has minimal side effects.
The main disadvantages of this treatment are:
- You are more likely to need another surgery for BPH later.3
- It may not work well for men with large prostates.
Related Information
References
Citations
Fitzpatrick JM (2007). Minimally invasive and endoscopic management of benign prostatic hyperplasia. In AJ Wein, ed., Campbell-Walsh Urology, 9th ed., vol. 3. pp. 2803–2844. Philadelphia: Saunders Elsevier.
Webber R (2006). Benign prostatic hyperplasia, search date May 2005. Online version of BMJ Clinical Evidence. Also available online: http://www.clinicalevidence.com.
Lourenco T, et al. (2008). Minimally invasive treatments for benign prostatic enlargement: Systematic review of randomised controlled trials. BMJ, 337(7676): a1662–a1669.
Credits
| By | Healthwise Staff |
| Primary Medical Reviewer | E. Gregory Thompson, MD - Internal Medicine |
| Specialist Medical Reviewer | Christopher G. Wood, MD, FACS - Urology, Oncology |
| Last Revised | March 23, 2010 |
| By: | Healthwise Staff | Last Revised: March 23, 2010 |
| Medical Review: | E. Gregory Thompson, MD - Internal Medicine Christopher G. Wood, MD, FACS - Urology, Oncology | |
© 1995-, Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions. | ||

Feedback